desonide and Facial-Dermatoses

Facial seborrheic dermatitis (SD), a chronic inflammatory skin condition, can impact quality of life, and relapses can be frequent. Three broad categories of agents are used to treat SD: antifungal agents, keratolytics, and corticosteroids. Topical therapies are the first line of defense in treating this condition.. Our objective was to critically review the published literature on topical treatments for facial SD.. We searched PubMed, Scopus, Clinicaltrials.gov, MEDLINE, Embase, and Cochrane library databases for original clinical studies evaluating topical treatments for SD. We then conducted both a critical analysis of the selected studies by grading the evidence and a qualitative comparison of results among and within studies.. A total of 32 studies were eligible for inclusion, encompassing 18 topical treatments for facial SD. Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment.. Promiseb

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Calcineurin Inhibitors; Ciclopirox; Dermatitis, Seborrheic; Dermatologic Agents; Desonide; Facial Dermatoses; Humans; Ketoconazole; Malassezia; Mometasone Furoate; Plant Preparations; Practice Guidelines as Topic; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Tacrolimus; Treatment Outcome; Vitamins

The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. Eighty-one adult patients were randomized to receive desonide 0.05% lotion or its vehicle, applied twice daily for 3 weeks under double-blind conditions. In the active treatment group, 88% of patients had their skin condition cleared or almost cleared and only two patients experienced cutaneous adverse events (rash and pruritus). The acceptability of the lotion was high; 95% of patients stated they would use this topical corticosteroid again. These data support the short-term use of desonide 0.05% lotion as a suitable agent for the short-term treatment of facial dermatitis.

Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Australia; Dermatitis, Atopic; Dermatitis, Seborrheic; Desonide; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Emulsions; Esthetics; Facial Dermatoses; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Probability; Reference Values; Treatment Outcome

Topics: Anti-Inflammatory Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dermatitis, Allergic Contact; Desonide; Facial Dermatoses; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Isocyanates; Loratadine; Masks; Pandemics; Patch Tests; Pneumonia, Viral; SARS-CoV-2; Young Adult

Topics: Anti-Inflammatory Agents; Dermatitis, Seborrheic; Desonide; Facial Dermatoses; Humans; Male; Middle Aged

Topics: Administration, Topical; Anti-Inflammatory Agents; Anticholesteremic Agents; Desonide; Diagnosis, Differential; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Facial Dermatoses; Female; Glucocorticoids; Humans; Lovastatin; Middle Aged; Patch Tests; Recurrence

Topics: Acne Vulgaris; Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Betamethasone; Child, Preschool; Clindamycin; Clotrimazole; Desonide; Erythema; Erythromycin Ethylsuccinate; Facial Dermatoses; Female; Glucocorticoids; Humans

Topics: Administration, Topical; Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; Desonide; Drug Therapy, Combination; Facial Dermatoses; Female; Humans; Hydrocortisone; Male; Middle Aged; Mouth; Oxytetracycline